Preview

FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology

Advanced search

Search


Order results by:     
 
Issue Title
 
Vol 5, No 2 (2012) COST EFFECTIVENESS OF ORAL PERICALCITOL IN PATIENTS WITH STAGE III-IV CHRONIC KIDNEY DISEASE AND SECONDARY HYPERPARATHYREOSIS Abstract  similar documents
A. V. Rudakova
"... paricalcitoldecreases proteinuria in patients with chronic kidney disease (CKD) and hyperparathyreosis. ..."
 
Vol 5, No 3 (2012) PHARMACOECONOMIC EVALUATION OF TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS ON DIALYSIS WITH CINACALCET Abstract  similar documents
R. I. Yagudina, V. G. Serpik
"... D and phosphorbinders in patients with end-stage renal disease on dialysis. Comparison was carried ..."
 
Vol 9, No 2 (2016) PHARMACO-ECONOMIC ANALYSIS OF COST IN TERMS OF MAINTENANCE OF PREFERENTIAL MEDICINES PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE ON THE TERRITORY OF KRASNOYARSK REGION Abstract  similar documents
T. V. Gaygolnik, I. V. Demko, E. N. Bochanova, A. Yu. Kraposhina, N. V. Gordeeva, I. A. Soloveva
"... in particular of providing preferential medicines patients with сhronic obstructive pulmonary disease (COPD ..."
 
Vol 9, No 2 (2016) PHARMACOECONOMIC ANALYSIS OF THE THERAPY OF СHRONIC OBSTRUCTIVE PULMONARY DISEASE PATIENTS IN HOSPITAL CONDITIONS Abstract  similar documents
E. E. Vidyakina, S. V. Malchikova
"... Objective. To determine the priority used to vital drugs in сhronic obstructive pulmonary disease ..."
 
Vol 5, No 3 (2012) PHARMACOECONOMIC STUDY OVER USE OF ANTICHOLINERGIC BRONCHODILATORS (SPIRIVA AND ATROVENT) FOR TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE Abstract  similar documents
A. U. Kulikov, I. A. Komarov
"... Currently, chronic obstructive pulmonary disease (COPD) is a 5-largest cause of death worldwide ..."
 
Vol 6, No 2 (2013) COST-EFFECTIVENESS ANALYSIS OVER USE OF TYROSINE KINASE INHIBITORS (TASIGNA AND GLEEVEC) FOR TREATMENT OF CHRONIC MYELOID LEUKEMIA IN THE CHRONIC PHASE AS FIRST-LINE THERAPY FOR DE NOVO PATIENTS Abstract  similar documents
R. I. Yagudina, A. Yu. Kulikov, I. A. Komarov
"... oncology diseases), and mortality due to leukemia is 220 000 patients. Pharmacoeconomic evaluation ..."
 
Vol 10, No 3 (2017) The strategies of drug supply for patients with chronic hepatitis C Abstract  similar documents
E. V. Kornilova, A. D. Ermolaeva, M. G. Rusanova, D. A. Andreev, M. V. Davydovskaya, T. N. Ermolaeva, A. g Pokatilo, K. I. Polyakova, V. A. Dubovtseva, K. А. Kokushkin, A. V. Devyatkin
"... The report reviews the options of drug supply for patients with chronic hepatitis C in the Russian ..."
 
Vol 8, No 1 (2015) PHARMACOEPIDEMIOLOGICAL EVALUATION OF HEPATOTROPIC THERAPY IN REAL CLINICAL PRACTICE Abstract  similar documents
D. V. Blinov, U. V. Zimovina, T. I. Ushakova
"... Chronic liver diseases are a serious problem and a common cause of suffering and death in all ..."
 
Vol 7, No 1 (2014) CLINICAL AND ECONOMIC ANALYSIS IN ASSESSMENT OF HEALTH CARE TECHNOLOGIES IN HEALTH CARE INSTITUTIONS Abstract  similar documents
I. B. Gaykovaya, A. T. Burbello, A. I. Ermakov, A. S. Fedorenko, T. V. Vavilova, M. V. Komok
"... of chronic infectious and inflammatory diseases and to evaluate the effectiveness of antiplatelet therapy. ..."
 
Vol 6, No 3 (2013) COST-UTILITY ANALYSIS OVER USE OF TYROSINE KINASE INHIBITORS (TASIGNA AND GLEEVEC) FOR TREATMENT OF CHRONIC MYELOID LEUKEMIA IN THE CHRONIC PHASE AS FIRST-LINE THERAPY FOR DE NOVO PATIENTS Abstract  similar documents
R. I. Yagudina, A. Yu. Kulikov, I. A. Komarov
"... Chronic myeloid leukemia (CML) accounts for roughly 20% of leucosis in adults, and this pathology ..."
 
Vol 11, No 2 (2018) Pharmacoeconomic analysis of treatment with nilotinib as the second line therapy in patients with chronic myeloid leukemia Abstract  similar documents
N. A. Avxentyev, M. Yu. Frolov, A. S. Makarov
"... Ilmatinib is currently the most widely used tyrosine kinase inhibitor for the treatment of chronic ..."
 
Vol 8, No 2 (2015) REASONS FOR DIFFICULTY OF THE PHARMACOECONOMIC ANALYSIS FOR ORPHAN DRUGS. WAYS FOR SOLUTIONS Abstract  similar documents
Andrey Vladislavovich Pavlysh, Aleksei Sergeevich Kolbin, Roman Andreevich Gapeshin, Stanislav Mikhailovich Malyshev
"... Orphan drugs are used for treatment of rare life-threatening diseases. There is no universal ..."
 
Vol 5, No 1 (2012) EСOLOGO-ECONOMIC PROBLEMS OF TECHNOGENIC INFLUENCE OF POLLUTION ON DISEASE OF THE POPULATION Abstract  similar documents
A. I. Borodin, E. M. Ovchinnikov
"... нетрудоспособность, хроническая заболеваемость, инвалид- ность, т.е. идут процессы потери трудовых ресурсов и ..."
 
Vol 7, No 2 (2014) ECONOMIC ANALYSIS OF USE OF IMMUNOCORRECTIVE PREPARATIONS FOR PREVENTION OF OFTEN RESPIRATORY INFECTIONS AND THEIR COMPLICATIONS AT CHILDREN OF SCHOOL AGE Abstract  similar documents
R. V. Maiorov, D. P. Derbenev
"... infections and considerable decrease direct and indirect cost on treatment of respiratory infectious diseases ..."
 
Vol 8, No 4 (2015) CLINICAL AND ECONOMIC EVALUATION OF THROMBOPOIETIN RECEPTOR AGONISTS IN THE TREATMENT OF CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA IN ADULTS Abstract  similar documents
E. A. Pyadushkina, M. Yu. Frolov, M. V. Avksentyeva
"... ) Eltrombopag and Romiplostim has been performed in patients with chronic idiopathic thrombocytopenic purpura ..."
 
Vol 7, No 3 (2014) THE ANALYSIS OF METHODOLOGIC CHARACTERISTICS OF RESEARCHES ON SOCIAL AND ECONOMIC BURDEN OF DISEASES IN RUSSIA IN THE FRAMES OF DEVELOPMENT OF STANDARD COST OF ILLNESS METHODOLOGY FOR THE HEALTH TECHNOLOGY ASSESSMENT Abstract  similar documents
V. I. Ignatyeva, M. V. Avxentyeva
"... of social and economic burden of disease) is one of the most widely used. Our objective was to analyze ..."
 
Vol 7, No 4 (2014) APPLICATION OF MULTIPLE-CRITERIA ANALYSIS FOR OPTIMIZATION OF FINANCING OF RARE DISEASES Abstract  similar documents
V. V. Omelyanovskiy, V. K. Fedyaeva, O. Yu. Rebrova
"... financing of rare disease drugs remains a serious problem for both foreign countries and our ..."
 
Vol 11, No 4 (2018) Modeling the effect of enzyme replacement therapy on life-threatening complications in patients with Fabry disease Abstract  similar documents
V. I. Ignatyeva, S. V. Moiseev, N. M. Bulanov, E. A. Karovajkina, A S. Moiseev
"... Fabry disease (FD) is a severe lysosome storage disease caused by congenital deficiency ..."
 
Vol 7, No 4 (2014) ANALYSIS OF GOVERNMENT PROCUREMENTS OF MEDICINES APPLIED IN RARE DISEASES THERAPY Abstract  similar documents
D. V. Fedyaev, V. K. Fedyaeva, V. V. Omelyanovsky
"... diseases. The analysis was conducted on the basis of 1499 selected trade procedures on rare disease drugs ..."
 
Vol 7, No 3 (2014) ASSESSMENT OF NECESSARY FINANCIAL EXPENSES ON THE DRUG SUPPLY OF THE PATIENTS WITH ORPHAN DISEASES IN THE RUSSIAN FEDERATION Abstract  similar documents
M. V. Sura, K. V. Gerasimova, V. V. Omelyanovskiy, M. V. Avksentyeva
"... with orphan diseases, included in the list of orphan diseases (24 diseases) by the RF Government Regulation ..."
 
Vol 11, No 3 (2018) Ocrelizumab – a monoclonal antibody – in the treatment of adult patients with multiple sclerosis: a systematic review Abstract  similar documents
D. L. Klabukova, M. E. Holownia-Voloskova, M. V. Davydovskaya, T. N. Ermolaeva, K. I. Polyakova, A. G. Fisun, K. A. Kokushkin
"... ; the intervention – ocrelizumab; the comparators – all disease-modifying treatments for MS; the outcomes ..."
 
Vol 7, No 1 (2014) PATIENTS WITH NEUROLOGICAL DISEASES: RATIONALE FOR PHARMACOECONOMIC EVALUATION OF COST OPTIMIZATION FOR MANAGEMENT WITH NEURON-SPECIFIC PROTEINS ASSESSMENT AS MARKERS OF INCREASED BLOOD-BRAIN-BARRIER PERMEABILITY Abstract  similar documents
D. V. Blinov
"... for NSP after the perinatal hypoxic-ischemic lesion of the CNS which reflects the chronic course ..."
 
Vol 9, No 2 (2016) EPIDEMIOLOGICAL FEATURES OF NON-ALCOHOLIC FATTY LIVER DISEASE IN NOVOSIBIRSK (SIBERIAN FEDERAL DISTRICT): REGIONAL DATA OF OPEN MULTICENTER PROSPECTIVE STUDY DIREG 2 Abstract  similar documents
V. V. Tsukanov, A. S. Yurkina, T. A. Ushakova, D. V. Blinov
"... Non-alcoholic fatty liver disease (NAFLD) is an important medical and social problem. Essentially ..."
 
Vol 6, No 4 (2013) Pharmacoeconomical analysis of use of the low-molecular weight heparins for prevention of the venous tromboembolism in the conditions of multidisciplinary hospital Abstract  similar documents
A. S. Kolbin, I. A. Vilyum, M. A. Proskurin, Yu. E. Balykina
"... тяжелой почечной недостаточностью с высоким риском развития венозных тромбоэмболических осложнений при ..."
 
Vol 9, No 4 (2016) PREVALENCE OF NON-ALCOHOLIC FATTY LIVER DISEASE IN REPUBLIC OF BASHKORTOSTAN (REGIONAL RESULTS OF DIREG 2 STUDY) Abstract  similar documents
D. Kh. Kalimullina, A. S. Yurkina, T. I. Ushakova, D. V. Blinov
"... Non-alcoholic fatty liver disease (NAFLD) is increasingly recognized as an important problem ..."
 
Vol 8, No 2 (2015) MAGNESIUM DEFICIENCY OF PATIENTS WITH HORMONE DEPENDENT DISEASES: PHARMACOEPIDEMIOLOGICAL PROFILE AND LIFE QUALITY ASSESSMENT Abstract  similar documents
Dmitry Vladislavovich Blinov, Juliana Vladimirovna Zimovina, Elena Anatol'evna Sandakova, Tat'yana Igorevna Ushakova
"... is more studied and known than in gynecology. Prevalence of MD in patients with gynecological diseases ..."
 
Vol 10, No 1 (2017) BIOLOGICAL THERAPY IN ADULT PATIENTS WITH ULCERATIVE COLITIS AND CROHN’S DISEASE: BUDGET IMPACT ANALYSIS Abstract  similar documents
E. A. Pyadushkina
"... ) and moderate or severe active Crohn’s disease (CT) with an unsatisfactory response, loss of response ..."
 
Vol 8, No 1 (2015) PHARMACOECONOMIC ANALYSIS OF EVEROLIMUS IMMUNOSUPRESSIVE THERAPY AFTER RENAL TRANSPLANTATION Abstract  similar documents
M. V. Avxentyeva, N. A. Avxentyev, M. Yu. Frolov, E. V. Derkach
"... impact for everolimus inclusion into 7 expensive diseases program (7EDP). 7 EDP is the special federal ..."
 
Vol 8, No 1 (2015) SOCIAL AND ECONOMIC BURDEN OF FIVE NATURAL FOCAL INFECTIONS IN THE RUSSIAN FEDERATION Abstract  similar documents
A. E. Platonov, N. A. Avksentyev, M. V. Avksentyeva, E. V. Derkach, O. V. Platonova, A. V. Titkov, N. M. Kolyasnikova
"... of disease) of five natural focal transmitted infectious diseases in theRussian Federationon the whole ..."
 
Vol 6, No 4 (2013) Pharmacoeconomic study of nutrition support in the conditions of current health care system in Russia Abstract  similar documents
I. A. Metelkin, R. I. Yagudina
"... of the main disease therapy standards, the hospitalization cost and NS cost) that proves stability ..."
 
Vol 12, No 1 (2019) Prevalence survey of musculoskeletal and connective tissue disorders in the Russian Federation Abstract  similar documents
T. A. Oleynikova, D. N. Pozhidaeva, A. Yu. Oreshko
"... Diseases of the musculoskeletal system and connective tissues are becoming more and more common ..."
 
Vol 9, No 1 (2016) COST-EFFECTIVENESS ANALYSIS OF BRENTUXIMAB VEDOTIN IN ADULTS WITH RELAPSED OR REFRACTORY HODGKIN’S LYMPHOMA Abstract  similar documents
G. R. Khachatryan, D. V. Fedyaev, M. V. Avxentyeva, V. S. Dombrovskiy
"... дорогостоящих препаратов для лечения онкологических заболеваний – бевацизумаба при метастатическом почечно ..."
 
Vol 9, No 2 (2016) Фармакоэкономический анализ терапии пациентов с ХОБЛ в стационарных условиях. Abstract  similar documents
"... По прогнозам экспертов Всемирной организации здравоохранения (ВОЗ) хроническая обструктивная ..."
 
Vol 10, No 2 (2017) Особенности клинико-экономической оценки терапии хронических заболеваний: несоответствие результатов классического фармакоэкономического и социально-экономического анализов Abstract  similar documents
,
"... -эффективность» и социально-экономического анализа схем фармакотерапии хронического заболевания. Показаны ..."
 
Vol 9, No 2 (2016) BUDGET IMPACT ANALYSIS OF PERAMPANEL FOR ADJUNCTIVE TREATMENT IN EPILEPSY PATIENTS 12 YEARS OF AGE AND OLDER FOR PARTIAL ONSET SEIZURES WITH OR WITHOUT SECONDARY GENERALIZATION AND PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN THE RUSSIAN FEDERATION Abstract  similar documents
V. R. Mkrtchyan, A. M. Sergeev, K. I. Pochigaeva, I. A. Shpak
"... и старше при парциальных приступах с вторичной генерализацией и без нее и при первично ..."
 
Vol 11, No 1 (2018) Presepsin as a sepsis biomarker Abstract  similar documents
K. A. Trunova
"... and severely burned patients. However, presepsin was not confirmed  as a marker of the disease severity ..."
 
Vol 12, No 1 (2019) Economic consequences of healthcare optimization for IBD patients in the Republic of Tatarstan Abstract  similar documents
T. P. Bezdenezhnykh, D. V. Fedyaev, G. R. Khachatryan, G. G. Arutyunov, K. V. Gerasimova
"... The integrated Model of health care for patients with inflammatory bowel disease (IBD) is based ..."
 
Vol 9, No 4 (2016) COMPARISON OF RECOMMENDED SCREENING PROGRAMS IN THE UNITED STATES, CANADA, THE NETHERLANDS AND GERMANY Abstract  similar documents
V. S. Dombrovskiy, G. R. Khachatryan
"... excluding infectious diseases. Sources of funding for such programs and information about ..."
 
Vol 5, No 1 (2012) COST OF ILLNESS ANALYSIS: TYPES, METHODOLOGY, RUSSIAN SPECIFICS Abstract  similar documents
R. I. Yagudina, I. Yu. Zinchuk, M. M. Litvinenko
"... consists in calculation of the expenses connected any given disease, without notice of effectiveness ..."
 
Vol 6, No 4 (2013) Фармакоэкономический анализ использования лираглутида в составе комбинированной терапии в лечении сахарного диабета 2-го типа Abstract  similar documents
A. Yu. Kulikov, I. V. Novikov
"... являлось изменение уровня HbА1с к концу исследования. Вторичные конечные точки включали изме- нения в ..."
 
Vol 7, No 2 (2014) CLINICAL AND ECONOMIC EVALUATION OF IVABRADINE USE IN STABLE ANGINA IN TERMS OF REPUBLIC OF BELARUS HEALTH CARE SYSTEM Abstract  similar documents
I. N. Kozhanova, I. S. Romanova, L. N. Gavrilenko, A. V. Patseev, M. M. Sachek
"... stable angina is a socially significant disease that requires significant financial costs ..."
 
Vol 9, No 2 (2016) EVALUATION OF RATIONALITY OF EXPENSES ON TREATMENT OF SEVERE COMMUNITY-ACQUIRES PNEUMONIA IN MULTI-PROFILE HOSPITAL Abstract  similar documents
I. V. Demko, N. V. Gordeeva, E. N. Bochanova, N. I. Golovina, A. Yu. Kraposhina, I. A. Soloveva, E. A. Sobko, T. V. Gaygolnik, S. V. Chubarova
"... disease and become the reason of complications, often fatal. Costs of the medicinal preparations ..."
 
Vol 5, No 2 (2012) PHARMACOEPIDEMIOLOGY OF PHYSICIANS’ INDICATIONS IN PATIENTS WITH POSTINFARCTIONCARDIOSCLEROSIS Abstract  similar documents
O. N. Kurochkinа, A. L. Khokhlov, N. M. Boyankova
"... that majority of patients with history of MI have received therapy referred to disease prognosis improvement. ..."
 
Vol 6, No 3 (2013) PHARMACOECONOMIC ANALYSIS OF DOCETAXEL IN THE ADJUVANT THERAPY OF BREAST CANCER Abstract  similar documents
R. I. Yagudina, I. Yu. Zinchuk
"... of research allows to increase the disease-free survival by 6,09%, and overall survival by 5,88% comparing ..."
 
Vol 9, No 1 (2016) COMPARATIVE CLINICAL AND ECONOMIC ANALYSIS OF THE INTENSIFICATION THERAPY IN PATIENTS WITH UNCONTROLLED DIABETES TYPE 2 USING BASAL INSULIN OR DAPAGLIFLOZIN Abstract  similar documents
V. I. Petrov, S. V. Nedogoda, M. Yu. Frolov, A. S. Salasyuk, I. N. Barykina, V. O. Smirnova, V. Yu. Khripaeva
"... ); – инфаркт миокарда; – хроническая сердечная недостаточность; – инсульт головного мозга; – ампутация нижних ..."
 
Vol 8, No 2 (2015) CLINICAL EFFICIENCY AND THE PHARMACOECONOMIC ANALYSIS OF ALLERGEN IMMUNOTHERAPY AT PATIENTS WITH MILD AND MODERATE ALLERGIC BRONCHIAL ASTHMA Abstract  similar documents
Elena Albertovna Sobko, Natalya Vladimirovna Gordeeva, Angelina Yurievna Kraposhina, Irina Anatolyevna Soloveva, Svetlana Vladimirovna Chubarova, Olga Petrovna Ishenko, Irina Vladimirovna Demko, Maria Michailovna Loktionova
"... , it is necessary to consider that the allergen immunotherapy interferes the progressing of the disease ..."
 
Vol 7, No 3 (2014) MODELI NG CLINICAL AND ECONOMIC OUTCOMES OF TESTING FOR LTBI WITH T-SPOT.TB IN IMMUNOCOMPROMISED CHILDREN Abstract  similar documents
V. I. Ignatyeva, M. V. Avxentyeva, V. V. Omelyanovsky, G. R. Khachatryan
"... weakening of immune status under the influence of some diseases or types of treatment could result ..."
 
Vol 9, No 1 (2016) PHARMACOECONOMIC SUBSTANTIATION OF APPLICATION OF GENETICALLY ENGINEERED BIOLOGICAL AGENTS IN OUT-PATIENT CONDITIONS Abstract  similar documents
O. Yu. Korennova, L. V. Shukil', S. N. Mal'tsev, I. A. Klinyshkov, N. M. Leganova, E. A. Turusheva, T. V. Kropotina
"... with rheumatic diseases (RD) by genetically engineered biological agents (GEBA) in conditions of round-the-clock ..."
 
Vol 8, No 4 (2015) ABC-, VEN- AND FREQUENCY ANALYSIS OF TREATMENT OF ATRIAL FIBRILLATION IN OUTCOME PATIENTS Abstract  similar documents
A. N. Korobeynikova, S. V. Malchikova
"... , for the treatment of heart disease it spends 8379.51 rubles., that is about 74.5%. The study found that received ..."
 
1 - 50 of 118 Items 1 2 3 > >> 

Search tips:

  • Search terms are case-insensitive
  • Common words are ignored
  • By default articles containing any term in the query are returned (i.e., OR is implied)
  • Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
  • Combine multiple words with AND to find articles containing all terms; e.g., education AND research
  • Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
  • Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
  • Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)